Full-house endoscopic sinus surgery with or without nasopharyngeal lymphoid tissue ablation for nasal polyps
Official title: Effect of Full-House Endoscopic Sinus Surgery With Versus Without Nasopharyngeal Lymphoid Ablation on Local Mucosal Inflammation in Chronic Rhinosinusitis With Nasal Polyps
Run by Tongji Hospital · NCT07245329 · Data updated 2026-11-12
This study will test whether adding nasopharyngeal lymphoid tissue ablation to full-house endoscopic sinus surgery helps adults with nasal polyps have less nasal inflammation and fewer recurrences.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 32 (estimated) |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | July 1, 2025 |
| Main results expected | August 1, 2026 |
| Study ends | August 1, 2026 |
| Registry record updated | November 24, 2025 |
| Trial ID | NCT07245329 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–65 with eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) who are surgical candidates and have a blood eosinophil count >0.3 × 10⁹/L are the ideal candidates.
✕Probably not a fit
Patients with cystic fibrosis, primary ciliary dyskinesia, immunodeficiency, systemic vasculitis/granulomatous disease, recent upper respiratory infection, or other significant comorbidities are excluded and are unlikely to benefit from this specific approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In a single-center randomized trial, 32 adults with eosinophilic chronic rhinosinusitis with nasal polyps will be assigned to full-house endoscopic sinus surgery (ESS) alone or ESS plus nasopharyngeal lymphoid tissue ablation. The primary outcome is change in inflammatory cell profiles measured at 1, 3, and 6 months after surgery. Secondary outcomes include inflammatory cytokine levels, symptom scores, endoscopic findings, polyp recurrence rates, and safety measures. Eligibility requires age 18–65 and blood eosinophils >0.3 × 10⁹/L, and all procedures and follow-up visits occur at Tongji Hospital in Wuhan.
Why it matters
Potential benefit: If successful, the addition of nasopharyngeal lymphoid tissue ablation could reduce mucosal inflammation and lower polyp recurrence, improving symptoms and potentially reducing the need for repeat surgery.
How similar studies have gone: Full-house ESS is an established surgical approach for CRSwNP, but adding nasopharyngeal lymphoid tissue ablation is a relatively novel strategy with limited prior evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18-65 years * Diagnosed with CRSwNP according to EPOS criteria * Blood eosinophil count \> 0.3 × 10⁹/L Exclusion Criteria: * Pregnant or lactating women. * Cystic fibrosis * primary ciliary dyskinesia * fungal ball rhinosinusitis * systemic vasculitis or granulomatous disease * malignancy * immunodeficiency. * Subjects with an upper-respiratory-tract infection within the past 4 weeks. * Clinically significant metabolic, cardiovascular, immune, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disorders, or any condition that, in the investigator's opinion, could interfere with outcome assessment or compromise patient safety. * Currently participating in another clinical trial or having participated in one within 30 days, or staff directly involved in this study.
Where it's running
-
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Yin Yao
- Email: Dr.yaoyin@hotmail.com
- Phone: 86 15071077020
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Metabolic and Immunologic Biomarkers in Chronic Rhinosinusitis with Nasal Polyps
This study tests whether metabolic and immune markers in nasal tissue and blood differ between people with nasal polyps and those without, to help understand CRSwNP and find potential diagnostic clues.
-
GSK5784283 as add-on therapy for chronic rhinosinusitis with nasal polyps
This study tests whether GSK5784283 added to standard care can help adults with chronic rhinosinusitis with nasal polyps feel better and have fewer symptoms.
-
GSK5784283 as add-on maintenance therapy for nasal polyps in chronic rhinosinusitis
This study tests whether adding GSK5784283 (Felcorekibart) to standard care helps people with chronic rhinosinusitis with nasal polyps.
-
Triamcinolone-loaded nanocapsules after endoscopic nasal surgery
This trial tests whether a triamcinolone acetonide–loaded nanocapsule spray is better than saline irrigation for healing after endoscopic nasal surgery in adults with chronic rhinosinusitis and nasal polyps.
-
Depemokimab monotherapy for chronic rhinosinusitis with nasal polyps in Japanese adults
This study tests depemokimab alone (without intranasal corticosteroids) in adults with chronic rhinosinusitis with nasal polyps in Japan.
-
Stopping mepolizumab or dupilumab to see if nasal polyps stay in complete remission.
This trial will test whether adults with well-controlled nasal polyps who have been on mepolizumab or dupilumab can safely stop the biologic and remain symptom-free.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.